Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14

Core Insights - Hemostemix Inc. is participating in Innovations in Wound Healing 2025, showcasing advancements in regenerative medicine for cardiovascular diseases, particularly Chronic Limb-Threatening Ischemia (CLTI) [1][2] - The company emphasizes the efficacy of its treatment, ACP-01, which has shown significant clinical trial results, including a 0% mortality rate and 83% limb preservation in treated patients over 4.5 years [3][10] - The recent enactment of Florida SB 1768 allows for the legal availability of ACP-01 to patients suffering from Peripheral Arterial Disease (PAD) and related conditions [4] Company Overview - Hemostemix is an autologous stem cell therapy platform company founded in 2003, recognized as a Technology Pioneer by the World Economic Forum [10] - The company has developed and patented VesCell™ (ACP-01), completing seven clinical studies with 318 subjects and publishing results in eleven peer-reviewed journals [10] - ACP-01 is positioned as a safe and clinically relevant treatment for various cardiovascular conditions, including PAD and CLTI [10] Clinical Evidence - Clinical studies indicate that ACP-01 effectively regenerates microvascular circulation, restores function, and improves quality of life for patients with severe ischemic peripheral arterial disease [2][3] - A study published by the University of Toronto reported that patients treated with VesCell experienced a significant reduction in ulcer size, from a mean of 146 mm² to 0.48 mm² within three months [3] - The treatment group showed a significantly lower rate of amputations and deaths compared to the placebo group, highlighting the treatment's effectiveness [3] Industry Context - The traditional approach in cardiovascular care has been to delay treatment until conditions worsen, which can lead to irreversible damage [8] - Hemostemix advocates for early intervention to restore circulation, arguing that timely treatment can enhance patient quality of life and reduce healthcare costs [9] - The company aims to change the standard of care in vascular treatments, promoting regenerative options before patients face severe complications [9]